Suggested blood donor deferral strategy regarding hepatitis B infections in China.

IF 1.5 4区医学 Q3 HEMATOLOGY

Transfusion Medicine Pub Date : 2024-04-01 Epub Date: 2024-01-23 DOI:10.1111/tme.13030

Ling Li, Rui Wang, Jin Guo, Liu He, Zhengmin Liu, Qianqian Qin, Jing Zhang, Shuo Wu, Liqin Huang, Hongwei Ge, Zhong Liu

{"title":"Suggested blood donor deferral strategy regarding hepatitis B infections in China.","authors":"Ling Li, Rui Wang, Jin Guo, Liu He, Zhengmin Liu, Qianqian Qin, Jing Zhang, Shuo Wu, Liqin Huang, Hongwei Ge, Zhong Liu","doi":"10.1111/tme.13030","DOIUrl":null,"url":null,"abstract":"Background: Hepatitis B virus (HBV) reactivity in individual immunologic and nucleic acid tests (NAT) tests does not represent the true infectious status of the blood donor. This study discusses the use of confirmatory tests to determine when deferral of blood donors is appropriate.Methods: HBsAg or HBV NAT reactive samples were confirmed via a neutralisation test. All the HBsAg reactive but neutralisation test negative samples were subjected to further anti-HBc testing. The receiver operating characteristic curve was used to obtain the best threshold value using signal-to-cut-off ratios of two HBsAg enzyme-linked immunosorbent assay reagents.Results: Of the 780 HBV reactive samples collected, there were 467 HBsAg reactive but HBV DNA negative samples, of which 65 (13.92%) and 402 (86.08%) were neutralisation test positive and negative, respectively. Of the 402, 91 samples (30% of tested samples) were anti-HBc reactive. HBV DNA positive specimens negative by virus neutralisation were >80% HBcAg positive. A screening strategy was proposed for Chinese blood collection agencies.Conclusion: These findings suggest that adopting a screening algorithm for deferring HBV reactive blood donors based on HBsAg and NAT testing followed with HBsAg S/CO consideration and HBcAg testing can be both safe and feasible in China.","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":"136-141"},"PeriodicalIF":1.5000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/tme.13030","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hepatitis B virus (HBV) reactivity in individual immunologic and nucleic acid tests (NAT) tests does not represent the true infectious status of the blood donor. This study discusses the use of confirmatory tests to determine when deferral of blood donors is appropriate.

Methods: HBsAg or HBV NAT reactive samples were confirmed via a neutralisation test. All the HBsAg reactive but neutralisation test negative samples were subjected to further anti-HBc testing. The receiver operating characteristic curve was used to obtain the best threshold value using signal-to-cut-off ratios of two HBsAg enzyme-linked immunosorbent assay reagents.

Results: Of the 780 HBV reactive samples collected, there were 467 HBsAg reactive but HBV DNA negative samples, of which 65 (13.92%) and 402 (86.08%) were neutralisation test positive and negative, respectively. Of the 402, 91 samples (30% of tested samples) were anti-HBc reactive. HBV DNA positive specimens negative by virus neutralisation were >80% HBcAg positive. A screening strategy was proposed for Chinese blood collection agencies.

Conclusion: These findings suggest that adopting a screening algorithm for deferring HBV reactive blood donors based on HBsAg and NAT testing followed with HBsAg S/CO consideration and HBcAg testing can be both safe and feasible in China.

查看原文本刊更多论文

关于中国乙型肝炎感染的献血者延期策略建议。

背景：单个免疫学和核酸检测（NAT）中的乙型肝炎病毒（HBV）反应性并不代表献血者的真实感染状况。本研究讨论了如何使用确证试验来确定何时适合推迟献血。对所有 HBsAg 反应但中和试验阴性的样本进一步进行抗 HBc 检测。利用两种 HBsAg 酶联免疫吸附测定试剂的信号-截止比，通过接收者操作特征曲线得出最佳阈值：在收集的 780 份 HBV 反应样本中，有 467 份 HBsAg 反应但 HBV DNA 阴性，其中 65 份（13.92%）和 402 份（86.08%）分别为中和试验阳性和阴性。在这 402 个样本中，有 91 个样本（占检测样本的 30%）呈抗 HBc 反应性。病毒中和检测呈阴性的 HBV DNA 阳性样本中，HBcAg 阳性率大于 80%。为中国采血机构提出了一种筛查策略：这些研究结果表明，在中国采用一种基于 HBsAg 和 NAT 检测的筛查算法来延迟 HBV 反应性献血者，然后再考虑 HBsAg S/CO 和 HBcAg 检测，既安全又可行。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transfusion Medicine 医学-血液学

CiteScore

2.70

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Transfusion Medicine publishes articles on transfusion medicine in its widest context, including blood transfusion practice (blood procurement, pharmaceutical, clinical, scientific, computing and documentary aspects), immunohaematology, immunogenetics, histocompatibility, medico-legal applications, and related molecular biology and biotechnology. In addition to original articles, which may include brief communications and case reports, the journal contains a regular educational section (based on invited reviews and state-of-the-art reports), technical section (including quality assurance and current practice guidelines), leading articles, letters to the editor, occasional historical articles and signed book reviews. Some lectures from Society meetings that are likely to be of general interest to readers of the Journal may be published at the discretion of the Editor and subject to the availability of space in the Journal.